Amgen Inc. (NASDAQ:AMGN)‘s stock had its “buy” rating reissued by equities researchers at Jefferies Group LLC in a note issued to investors on Monday, July 17th. They presently have a $195.00 target price on the medical research company’s stock. Jefferies Group LLC’s target price would suggest a potential upside of 15.09% from the stock’s previous close.
A number of other equities research analysts also recently issued reports on the company. Mizuho set a $195.00 price target on Amgen and gave the company a “buy” rating in a research note on Saturday, May 6th. UBS AG reiterated a “neutral” rating and set a $174.00 price objective (down from $175.00) on shares of Amgen in a research note on Monday, May 22nd. BMO Capital Markets reiterated a “buy” rating and set a $198.00 price objective (down from $200.00) on shares of Amgen in a research note on Monday, May 22nd. Leerink Swann restated a “market perform” rating and issued a $161.00 price target on shares of Amgen in a research note on Thursday, June 22nd. Finally, Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $189.00 price target on shares of Amgen in a research note on Friday, July 14th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $186.64.
Amgen (NASDAQ:AMGN) traded up 0.19% during midday trading on Monday, reaching $169.43. 1,571,584 shares of the company’s stock traded hands. The firm has a market cap of $123.63 billion, a price-to-earnings ratio of 15.43 and a beta of 1.35. The stock’s 50 day moving average price is $174.48 and its 200 day moving average price is $167.49. Amgen has a 1-year low of $133.64 and a 1-year high of $184.21.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the previous year, the firm earned $2.84 EPS. Amgen’s revenue was up 2.1% on a year-over-year basis. Equities research analysts anticipate that Amgen will post $12.57 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Amgen’s (AMGN) “Buy” Rating Reiterated at Jefferies Group LLC” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/08/11/amgen-inc-amgn-earns-buy-rating-from-jefferies-group-llc-updated-updated-updated.html.
In related news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the sale, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the stock. Veritable L.P. increased its stake in Amgen by 13.5% in the second quarter. Veritable L.P. now owns 29,522 shares of the medical research company’s stock valued at $5,085,000 after buying an additional 3,508 shares in the last quarter. OxFORD Asset Management LLP increased its position in shares of Amgen by 42.2% in the second quarter. OxFORD Asset Management LLP now owns 16,946 shares of the medical research company’s stock worth $2,919,000 after buying an additional 5,030 shares during the period. Evercore Wealth Management LLC increased its position in shares of Amgen by 13.1% in the second quarter. Evercore Wealth Management LLC now owns 14,334 shares of the medical research company’s stock worth $2,469,000 after buying an additional 1,656 shares during the period. Ally Financial Inc. increased its position in shares of Amgen by 108.3% in the second quarter. Ally Financial Inc. now owns 25,000 shares of the medical research company’s stock worth $4,306,000 after buying an additional 13,000 shares during the period. Finally, Global Endowment Management LP acquired a new position in shares of Amgen during the second quarter worth about $3,393,000. 79.53% of the stock is owned by hedge funds and other institutional investors.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
What are top analysts saying about Amgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen Inc. and related companies.